natural pharmaceuticals derived From Cannabis and other medicinal plants
Recently Received Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product
- Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
- Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan
Chief Executive Officer
Bernard Fortier is a graduate from the MBA program at l'école des Hautes Études Commerciales (HEC) in Montreal, with over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields.
Mr. Fortier spent 5 years in the USA working in the therapy and rehabilitation market, having graduated from the physiotherapy program at Laval University. His experience in the USA enabled him to work on business development and management early in his career. After completing his MBA in 2001, he joined the pharmaceutical industry with a biotechnology company. He spent 8 years in various key commercial roles at Serono Canada (now EMD Serono) in the Multiple Sclerosis field, including National Sales Manager for the Neurology business unit.
In 2010, Bernard became the Country Manager for Nutricia Canada, the specialized medical nutrition division of Groupe Danone. He was recruited in 2012 to launch a new pharmaceutical company called Orimed Pharma. Through licensing deals and internal product development, the company's portfolio grew from 3 to 10 products within 4 years.
Chairman of the Board of Directors
Previously, Mr. Rancourt, and Dr Chamberland, have worked together on several other projects. Mr. Rancourt assumed the title of CEO of Tetra five (5)months ago. He is highly experienced in management, start-up, and commercial strategies for human and agriculture products. Mr. Rancourt is also a consultant on several commercial strategy committees including FIA and IRZC. He has tremendous practical experience that provided him with expertise in many fields ranging from metals to the complex area of human and animal natural health products.
Over the years, Mr. Rancourt developed an expertise in the area of negotiation. He successfully negotiated collective agreements for Stations Radiophonique Régional de Télémédia Québec as well as agreements for companies in the metal and Agro-Food businesses. In addition, he negotiated license agreements as well as several technology transfers.
Over the last ten years, Mr. Rancourt worked as a consultant to re-organize the operations of companies on behalf of several venture capital investment funds. He has an important network of contacts in the human and animal commercial market in multiple countries. Codrah NA is a global commercialization consulting group that was created with many of these contacts to assist companies to commercialize products around the world.
Mr. Rancourt studied at the Séminaire Sherbrooke from 1969 to1971 and subsequently the University of Sherbrooke (Physical Education). He also successfully completed training in Marketing WarFare. He is often asked by investors to act as a consultant/guide to Presidents of companies.
Dr. W.M. (Bill) Cheliak
Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of experience as an entrepreneur having helped establish companies in a wide variety of life science fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. He brings extensive deal making experience with the pharmaceutical industry. He currently serves as a Director for Solarvest (SVS). Dr. Cheliak is Vice Chair of the Government of Canada’s Networks Centres Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee.
Co Founder / VP Business development
Ryan has an extensive background in hydroponic equipment manufacturing and distribution throughout North America. As A provider to the industry he worked closely with medicinal cannabis growers in Canada as well as in the United States. over the past five years he has worked in conjunction with medicinal cannabis producers and research facilities around the world focused on the Genetic selection , standardization and breeding of medicinal cannabis Strains to address specific medical symptoms. he has worked closely with doctors and patients improving there access to and knowledge of cannabis therapeutics. Ryan has a unique understanding of both cultivation practices and the needs of patients that will serve as a significant asset to the diversification of grow pros cannabis inc.
Norm’s 30 year career with the RCMP saw him involved in various task force operations in Canada as well as overseas in Spain and the Dominican Republic.
A former manager of the Health Canada MMAR (medical marijuana access regulations) program. She will bring over 30 years of experience and expertise in government regulations and policy management to GrowPros and its partners.
Andre has held CEO and Director positions for several publicly listed resource companies in Canada including Everton Resources, Majescor Resources and Mazorro Resources.
Steve has been in the hydroponic and medical cannabis business for over 17 years. During this time, he has established an international network of business partners while conducting medical cannabis growing seminars. Steve has developed an acute expertise as a large-scale medical marijuana producer.
Director – Medical Research
Charles has worked as a graduate researcher in basic science laboratories for six years. He obtained his B.Sc. in 2009 from the University of Ottawa, where he is currently concluding his Doctoral studies. In addition to a comprehensive knowledge of basic neurobiology, Charles has extensive experience in concisely disseminating complex scientific concepts to groups of varying levels of expertise.
Sabino Di Paola
Chief Financial Officer
Sabino Di Paola, is a graduate of Concordia University, and also serves as the CFO of several, publicly listed junior companies with operations in Canada and abroad. He has close to ten years' experience in audit, finance and accounting while working as an auditor for PricewaterhouseCoopers and BDO Canada, and has been involved with numerous financing and spin out transactions. He is responsible for all aspects of financial reporting and corporate governance for Tetra Bio-Pharma.
Vice President, Investor Relations & Corporate Communications
Mr. Miller has over a decade of experience in the Biotech/Pharma industry. Most recently, he served as Director, Investor Relations and Corporate Communications at IntelGenx Corp. where he successfully built their shareholder communications program, resulting in substantial growth in their website traffic and social media hits. Mr. Miller joined Paladin Labs in 2001 where he held various positions including Manager, Investor Relations where he successfully built their investor relations program. Following his tenure at Paladin Labs he moved into the role as an investor relations consultant working for Christensen IR, heading their life science practice and as an independent where he has built award winning investor relations programs. Mr. Miller is the Past President of CIRI (Canadian Investor Relations Institute) Quebec Chapter where he served two terms (2009 - 2012) and (2005 - 2007). Mr. Miller will be contributing to improving the company's visibility in the capital markets and leveraging his international experience at broadening its shareholder base.
Vice President, Sales
Mr. Courchesne has over 25 years' sales and management experience in the retail environment working for various companies such as Evian Spring Water (Danone) and Pfizer Canada.
In the last 15 years, he has been working in both the pharmacy and health food channels where he successfully held positions in Quebec as National Sales Manager. In his previous companies, he rapidly reorganized the sales forces enabling the teams to outperform their sales and profit objectives. Since 2010 Mr. Courchesne has been working as an independent consultant helping various brands in many aspects of their business such as marketing, strategy and goal establishment while enabling them to solidify their presence at store level.
Vice President, Finance and Business Development
Mr. Bechard brings more than 20 years' experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry. As Vice President of Finance and Business Development, Mr. Bechard will be responsible for leading the charge on business development as it relates to the pharmaceutical side of the business and managing the financial side of the company.
During his tenure at RBC Lifesciences Funds I&II, Mr. Bechard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Bechard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Bechard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.